· Dresden 2006 - Vom Nihilismus zum Algorithmus ·

Zytogenetik als Möglichkeit zur Unterscheidung von Subtypen myelodysplastischer Syndrome

Literatur | Vortrag siehe hier

Autor: Priv.-Doz. Dr. med. Detlef Haase, Universitätsklinikum Göttingen, Göttingen

Quellenangabe: Deutsches MDS-Forum - Dresden 2006

Stand: 27.11.2006

Boultwood J, Fidler C, Strickson AJ, Watkins F, Gama S, Kearney L, Tosi S, Kasprzyk A, Cheng J-F, Jaju RJ, and Wainscoat JS.
Narrowing and genomic annotation of the commonly deleted region of the 5q syndrome. Blood 2002;99:4638-4641. PM:12036901
[Medline]
Chen G, Zeng W, Miyazato A, Billings E, Maciejewski JP, Kajigaya S, Sloand EM, and Young NS.
Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities.
Blood 2004;13:4210-4218. PM:15315976
[Medline]
Giagounidis AAN, Germing U, Strupp C, Hildebrandt B, Heinsch M and Aul C.
Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup.
Ann Hematol 2005;84:569-571. PM:15891887
[Medline]
Giagounidis AAN, Haase S, Germing U, Schlegelberger B, Wilkens L, Büsche G, Kreipe HH, Wysk J, Grips K-H, Grabenhorst U, Rothmann F, Lübbert M, Ganser A, Aivado M, Heinsch M and Aul C.
Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-α: a phase II study.
Ann Hematol 2005;84:1432-1584. PM:15785949
[Medline]
Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J.
International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes.
Blood 1997;89:2079-2088. PM:9058730
[Medline]
Haase D, Steidl C, Schanz J, Schabla R, Pfeilstöcker M, Nösslinger T, Hildebrandt B, Kuendgen A, Lübbert M, Kunzmann B, Giagounidis A, Aul C, Trümper L, Krieger O, Fonatsch C, Valent P, Stauder R, Germing U.
Correlation Of Cytogenetic Findings With Morphology, Clinical Course And Prognosis In 2124 Patients With MDS [abstract].
Blood 2005;106:532.
Pedersen-Bjergaard J, Andersen MK, Christiansen DH, Nerlov C.
Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia.
Blood 2002;99:1909-1912. PM:11877259
[Medline]
Kavita KR, John MA, Ho A, Thomas NSBT, Mufti GJ.
Early and sustained response to Azazcytidine in high-risk MDS patients with monosomy 7 correlates with increased apoptosis and not CDKN2B demethylation [abstract].
Blood 2005;106:2530.
List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB.
Efficacy of Lenalidomide in Myelodysplastic Syndromes.
New Engl J Med 2005;352:549-557. PM:15703420
[Medline]
Lübbert M, Wijermans P, Kunzmann R, Verhoef G, Bosly A, Ravoet MA, Ferrant A.
Cytogenetic responses in high-risk myelodysplastic syndrome folowing low-dose treatment with the DNA metzhylation inhibitor 5-aza-2’-deoxycytidine.
Br J Haematol 2001;114:349-357. PM:11529854
[Medline]
Nagarajan L.
Molecular analysis of the 5q- chromosome.
Leuk Lymphoma 1995;17:361-366. PM:7549826
[Medline]
National Comprehensive Cancer Network (NCCN) Myelodysplastic panel members. NCCN practice guidelines: myelodysplastiic syndromes v1. 2005. http://www.nccn.org/professionals/physician.gls/PDF/mds.pdf. Accessed August 12, 2005
Olney HJ, Le Beau MM. In Deeg HJ.
Myelodysplastic syndromes.
New York, Springer-Verlag; 2005:55
Pellagatti A, Cazzola M, Giagounidis AAN, Malcovati L, Della Porta MG, Killick S, Campbell LJ, Wang L, Langford CF, Fidler C, Oscier D, Aul C, Wainscoat JS, and Boultwood J.
Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype.
Blood 2006;108:337-345. PM:16527891
[Medline]
Sole F, Luno E, Sanzo C, Espinet B, Sanz GF, Cervera J, Calasanz MJ, Cigudosa JC, Milla F, Ribera JM, Bureo E, Marquez ML, Arranz E, Florensa L.
Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes.
Haematologica 2005;90:1168-1178. PM:16154839
[Medline]